Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53

Journal of Molecular Recognition

Volumn 12, Issue 2, 1999, Pages 141-152

  Giovane, Christine ^a   Travé, Gilles ^a   Briones, Amélie ^b   Lutz, Yves ^b   Wasylyk, Bohdan ^b   Weiss, Etienne ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b CNRS/UPR 9003 ^*

Author keywords

Antibody inhibition; E6 protein; HPV16; In vitro; P53 degradation; Single chain antibody

Indexed keywords

CARCINOMA CELL; CELL ULTRASTRUCTURE; DEGRADATION; DISEASE DIAGNOSIS; ESCHERICHIA COLI; GENE TARGETING; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN DEGRADATION; WART VIRUS 16;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0033103068     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1352(199903/04)12:2<141::AID-JMR453>3.0.CO;2-O     Document Type: Article

References (60)

1. Barbosa, M. S. and Schlegel, R. (1989). The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene, 4, 1529-1532.
2. Beaudenon, S., Kremsdorf, D., Croissant, O., Jablonska, S., Wain-Hobson, S. and Orth, G. (1986). A novel type of human papillomavirus associated with genital neoplasias. Nature, 321, 246-249.
3. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W. G., Westmoreland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E., Rutherford, E. J., Hicklich, J. K. and Inglis, S. C. (1996). A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523-1527.
4. Chen, J. J., Reid, V., Band, V. and Androphy, E. J. (1995). Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science, 269, 529-531.
5. Cochet, O., Königsberg, M., Delumeau, I., Virone-Oddos, A., Multon, M., Fridman, W. H., Schweighoffer, F., Teillaud, J. L. and Tocqué, B. (1998). Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res., 58, 1170-1176.
6. Crook, T., Tidy, J. A. and Vousden, K. H. (1991). Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67, 547-556.
7. Daniels, P. R., Sanders, C. M., Coulson, P. and Maitland, N. J. (1997). Molecular analysis of the interaction between HPV type 16 E6 and human E6-associated protein. FEBS Lett. 416, 6-10.
8. Daniels, P. R., Sanders, C. M. and Maitland, N. J. (1998) charactéristion of the interactions of human papillomavirus type 16 E6 with p53 and E6-associated protein in insect and human cells. J. Gen. Virol. 79, 489-499.
9. Deau, M., Favre, M. and Orth, G. (1991). Genetic heterogeneity among human papillomaviruses associated with epidermodysplasia verruciformis: evidence for multiple allelic forms of HPV5 and HPV8 E6 genes. Virology 184, 492-503.
10. Demers, G. W., Foster, S. A, Halbert, C. L. and Galloway, D. A. (1994). Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA, 91, 4382-4386.
11. Deshane, J., Cabrera, G., Grim, G. E., Siegal, G. P., Pike, J., Alvarez, R. D. and Curiel, D. T. (1995). Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erb-B-2 single-chain antibody. Gynecol. Oncol. 59, 8-14.
12. Desplancq, D., King, D. J., Lawson, A. D. J. and Mountain, A. (1994). Multimerization behaviour of single chain Fv variants for the tumor-binding antibody B 72.3. Protein Engng 7, 1027-1033.
13. Dyson, N., Howley, P. M., Munger, K. and Harlow, E. (1989). The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-937.
14. Farthing, A. J. and Vousden, K. H. (1994). Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol., 2, 170-173.
15. Foster, S. A., Demers, G. W., Etsheid, B. G. and Galloway, D. A. (1994). The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol., 68, 5698-5705.
16. Gao, L., Chain, B., Sinclair, C., Crawford, L., Zhou, J., Morris, J., Zhu, X. and Strauss, H. (1994). Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J. Gen. Virol. 75, 157-164.
17. Giovane, C., Schwalbach, G. and Weiss, E. (1997). In vivo labeling of overexpressed recombinant proteins in E. coli. Biotechniques 22, 796-797.
18. Gram, H., Marconi, L., Barbas III, C. F., Collet, T. A., Lerner, R. A. and Kang, A. S. (1992). In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc. Natl Acad. Sci. USA 89, 3576-3580.
19. Harlow, E. and Lane, D. P. (1989). Antibodies: a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
20. He, Y. and Huang, L. (1997). Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from the U6 promoter. Cancer Res. 57, 3993-3999.
21. Huibregtse, J. M. and Beaudenon, S. L. (1996). Mechanism of HPV E6 proteins in cellular transformation. Semin. Cancer Biol. 7, 317-326.
22. Huibregtse, J. M., Scheffner, M. and Howley, P. M. (1993). A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 and 18. EMBO J., 10, 4129-4135.
23. Jannot, C. B., Beerli, R. R., Mason, S., Gullick, W. J. and Hynes, N. E. (1996). Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition in tumor cells. Oncogene 13, 275-282.
24. Janssen-Dürr, P. (1996). How viral oncogenes make the cell cycle. Trends Genet., 12, 270-275.
25. Jeon, S., Lynn-Hoffmann, B. and Lambert, P. F. (1995). Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol., 69, 2989-2997.
26. Kabat, E. A., Wu, T., Perry, H. M., Gottesman, K. S. and Foeller, C. (1991). Sequences of Proteins of Immunological interest, 5th Edn. U S Department of Health and Human Services, Bethesda, MD.
27. Kanda, T., Watanebe, S., Zanma, S., Sato, H., Furuno, A. and Yoshike, K. (1991). Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology 185, 536-543.
28. Keen, N., Elston, R. and Crawford, L. (1995). Interaction of the E6 protein of human papillomavirus with cellular proteins. Oncogene, 9, 1493-1499.
29. Kessis, T. D., Slebos, R. S., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L and Cho, K. R. (1993). Human papillomavirus 16E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl Acad. Sci. USA, 90, 3988-3992.
30. Klingelhutz, A. J., Foster, S. A. and McDougall, J. K. (1996). Telomerase activation by th E6 gene product of human papillomavirus type 16. Nature, 380, 79-82.
31. Laimins, L. A. (1996). Human papillomaviruses target differentiating epithelia for virion production and malignant conversion. Semin. Virol., 7, 305-313.
32. Leveillard, T., Andera, L., Bissonnette, N., Schaeffer, L., Bracco, L., Egly, J. M. and Wasylyk, B. (1996). Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 15, 1645-1624.
33. Li, X. and Coffino, P. (1996). High-risk human papillomavirus E6 protein has two distinct sites within p53, of which only one determines degradation. J. Virol., 70, 4509-4516.
34. Liang, X. H., Volkmann, M., Klein, R., Herman, B. and Lockert, S. J. (1993). Co-localization of the tumor suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene, 8, 2645-2652.
35. Madrigal, M., Jaenicke, M. F., Sevin, B. U., Perras, J., Estape, R., Penalver, M. and Averette, H. E. (1997). In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol. Oncol. 64, 1825-1832.
36. Meneguzzi, G., Cerni, C., Kieny, M. P. and Lathe, R. (1991). Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181, 62-69.
37. Mhashilkar, A. M., Biswas, D. K., Lavecchio, J., Pardee, A. D. and Marasco, W. A. (1997). Inhibition of human immunodeficiency virus type 1 replication in vitro by a combination of anti-tat single-chain intrabodies and NF-KB antagonists. J. Virol. 71, 6486-6494.
38. Nieba, L., Honegger, A., Krebber, C. and Plückthun, A. (1997). Disrupting the hydophobic patches at the antibody variable/ constant domain interface: improved in vivo folding and physical characterisation of an engineered scFv fragment. Protein. Engng 10, 435-444.
39. Orfanoudakis, G., Karim, B., Bourel, D. and Weiss, E. (1993). Bacterially-expressed Fabs of monoclonal antibodies neutralizing tumor necrosis factor alpha in vitro retain full binding and biological activity. Molec. Immunol. 30, 1519-1528.
40. Phelps, W. C., Yee, C., Münger, L. and Howley, P. M. (1988). The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell, 53, 539-547.
41. Pim, D., Massimi, P. and Banks, L. (1997). Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15, 257-264.
42. Raag, R. and Whitlow, M. (1995). Single-chain Fvs. FASEB J. 9, 73-80.
43. Rapp, L. and Chen, J. J. (1998). The papillmavirus E6 proteins. Biochim. Biophys. Acta 1378, 1-19.
44. Reik, L. M., Maines, S. L., Ryan, D. E., Lewin, W., Bandiera, S. and Thomas, P. E. (1987). A simple non-chromatographic purification procedure for monoclonal antibodies. J. Immunol. Meth. 100, 123-130.
45. Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular cloning: a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
46. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. and Howley, P. M. (1990). The E6 protein encoded by human papillomavirus types 16 and 18 promotes and degradation of p53. Cell, 63, 1129-1136.
47. Scheffner, M., Münger, K., Byrne, J. C. and Howley, P. M. (1991). The state of the p53 and retinoblastoma genes in human cervical cell lines. Proc. Natl Acad. Sci. USA. 88, 5523-5527.
48. Scheffner, M., Takahashi, T., Huibregtse, J. M., Minna, J. D. and Howley, P. M. (1992). Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J. Virol. 66, 5100-5105.
49. Slebos, R. J. C., Kessis, T. D., Chen, A., Han, S. M., Hedrick, L. and Cho, K. R. (1995). Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro. Virology 208, 111-120.
50. Stacey, S. N., Eklund, C., Jordan, D., Smith, N. K., Stern, P. L., Dillner, J. and Arrand, J. A. (1994). Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies. Oncogene 9 635-645.
51. Tan, T. M. C. and Ting, R. C. Y. (1997). In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. 55, 4599-4605.
52. Thomas, M., Matlashewski, G., Pim, D. and Banks, L. (1996). Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 13, 265-273.
53. Tommasino, M. and Crawford, L. (1995). Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. BioEssays, 17, 509-518.
54. Tsumoto, K., Nishimiya, Y., Kasai, N., Ueda, H., Nagamune, T., Ogasahara, K., Yutani, K., Tokuhisa, K., Matsushima, M., Kumagai, I. (1997). Novel selection method for engineered antibodies using the mechanism of Fv fragment stabilization in the presence of antigen. Protein Engng 10, 1311-1318.
55. Wang-Johanning, F., Gillepsie, G. Y., Grim, J., Rancourt, C., Alvarez, R. D., Siegal, G. P. and Curiel, D. T. (1998). Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects. Cancer Res. 58, 1893-1900.
56. Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T. and Winter, G. (1989). Binding activities of a repertoire of single immunoglobulin variable domains secreted from E. coli. Nature 341, 544-546.
57. Werness, B. A., Levine, A. J. and Howley, P. M. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248, 76-79.
58. Whitlow, M., Filpula, D., Rollence, M. L., Feng, S. and Wood, J. F. (1994). Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Engng 7, 1017-1026.
59. Wu, Y., Duan, L., Zhu, M., Hu, B., Kubota, S., Bagasra, O. and Pomerantz, R. J. (1996). Binding of intracellular anti-rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J. Virol. 70, 3290-3297.
60. zur Hausen, H. (1996). Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta. 1288, 55-78.